查詢結果分析
相關文獻
- 大腸直腸阻塞病人接受自動擴張性金屬支架置入--病歷報告及文獻回顧
- Tuberculosis Presenting with Pelvic Mass, Peritoneal Lesions, and Elevation of Serum CA125 Mimicking Malignant Tumor: A Case Report
- Preoperative Evaluation of Serum CA125 and CA19-9 Levels in Patients with a Pelvic Mass
- Cystic Lymphangioma in the Pelvic Cavity
- CT evaluation of spread of diseases between pelvis and extrapelvic sites
- 懷孕時的骨盆腔腫瘤
- 影像上的骨盆腔腫瘤:卵巢扭轉
- Castleman's Disease in Pelvis
- 模仿婦科腫瘤的胃腸道基質瘤:病例報告及文獻回顧
- 女性骨盆腔腫瘤概論與個案分享
頁籤選單縮合
題名 | Preoperative Evaluation of Serum CA125 and CA19-9 Levels in Patients with a Pelvic Mass=術前評估骨盆腔腫瘤患者血清中CA125及CA19-9之濃度 |
---|---|
作者 | 黃莉文; 李鎡堯; | 書刊名 | 中華民國婦產科醫學會會刊雜誌 |
卷期 | 36:4 1997.12[民86.12] |
頁次 | 頁125-131 |
分類號 | 417.38 |
關鍵詞 | 骨盆腔腫瘤; CA125; CA19-9; Pelvic mass; |
語文 | 英文(English) |
中文摘要 | 目的:CA125和CA19-9是臨床上偵測卵巢癌最常用的腫瘤指標。本研究目的在評 估合併檢驗血清中CA125及CA19-9之濃度,能否早期偵測惡性卵巢瘤。 方法:本研究收集99位骨盆腔腫瘤之患者,在接受腹腔鏡或剖腹探查手術前,抽血檢驗 血清中CA125及CA19-9濃度。針對術後病理報告及血清中CA125及CA19-9濃度加以分析, 以測定CA125及CA19-9用於診斷卵巢癌之敏感性及專一性。 結果:在99位骨盆腔腫瘤患者中,有31位經病理診斷為惡性卵巢癌患者。檢查結果發 現血清CA125>35U/ml在診斷卵巢癌的敏感性及專一性方面均較CA19-9>37U/ml為佳。若患者 血清CA125>65U/mL,則其預測為卵巢癌的機率是73.9%,而其專一性為91.2%,因此患者血 清中CA125>65 U/mL是預測惡性卵巢癌之重要指標。若合併檢驗血清中CA125及CA19-9之濃 度,取兩項腫瘤指標之一有異常上升為陽性,則其術前偵測卵巢癌之敏感性較單一CA125檢 驗顯著提高(80.6%對67.7%, P<0.05)。 結論:本研究得知CA125是臨床預測卵巢癌的重要指標,但若合併使用CA19-9則可提高 術前偵測卵巢癌的敏感性。 |
英文摘要 | Objective: CA1 25 and CA19-9 are useful tumor markers for detection of ovarian tumors. The aim of this study was to evaluate whether concomitant measurements of CA125 and CA19-9 could aid in the early detection of ovarian malignancies. Methods: Serum levels of CA125 and CA19-9 were measured in 99 patients with pelvic masses who were about to undergo laparotomy or laparoscopy. The pathologic reports and operative findings for these patients were reviewed and the serum levels of CA125 and CA19-9 were evaluated to determine their sensitivity and specificity for identifying patients with ovarian malignancies. Results: In 31 patients with ovarian malignancies, we found that at a level >35 U/mL, CA125 was more sensitive and specific than CA19-9 at a level >37 U/mL. At a level >65 U/mL, CA1 25 had a positive predictive value of 73.9% and a specificity of 91.2%. In the diagnosis of ovarian malignancy, when the patient had an elevation of CA125 and CA19-9, the sensitivity was higher than CA125 alone (80.6% vs. 67.7%, p<0.05). Conclusion: This study suggests that CA125 is a more reliable tumor marker in predicting an ovarian malignancy. However, the concomitant measurements of serum CA125 and CA19-9 offer a higher sensitivity than CA125 or CA19-9 assay alone. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。